当前期刊: Liver International Go to current issue    加入关注   
显示样式:        排序: IF: - GO 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Multicentre, Phase II Study of Gemcitabine and S‐1 in Patients with Advanced Biliary Tract Cancer: TG1308 Study
    Liver Int. (IF 5.542) Pub Date : 2020-05-28
    Nai‐Jung Chiang; Ming‐Huang Chen; Shih‐Hung Yang; Chiun Hsu; Chia‐Jui Yen; Hsiao‐Hui Tsou; Yung‐Yeh Su; Jen‐Shi Chen; Yan‐Shen Shan; Li‐Tzong Chen

    Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that the median overall survival and incidence of significant neutropenia after gemcitabine plus S‐1 (GS) and GC treatments were comparable. This study evaluates the efficacy and safety of the modified GS regimen.

    更新日期:2020-05-28
  • Chronological change in alpha‐fetoprotein levels in hepatocellular carcinoma after eradication of hepatitis C virus
    Liver Int. (IF 5.542) Pub Date : 2020-05-28
    Tsuyoshi Fukumoto; Tatsuya Minami; Ryosuke Tateishi; Kazuhiko Koike

    We read with interest the article by Chen et al. reporting proportion of time covered by imaging modality was associated with increased early detection of hepatocellular carcinoma (HCC). 1 However, in this study, alpha‐fetoprotein (AFP) was not assessed as a surveillance tool because of low rate of AFP measurements. In the era of direct‐acting antivirals (DAA) almost all patients could achieve sustained

    更新日期:2020-05-28
  • Genetic variants in the MTHFR are not associated with fatty liver disease
    Liver Int. (IF 5.542) Pub Date : 2020-05-27
    Antonio De Vincentis; Rosellina Margherita Mancina; Jussi Philamajäki; Ville Männistö; Salvatore Petta; Paola Dongiovanni; Anna Fracanzani; Luca Valenti; Federica Tavaglione; Stefano Romeo; Umberto Vespasiani‐Gentilucci

    The common missense sequence variants of methylenetetrahydrofolate‐reductase (MTHFR ), rs1801131 (c.A1298C) and rs1801133 (c.C677T), favor the development of hyperhomocysteinemia and diminished DNA methylation. Previous studies, carried out in small series and with suboptimal characterization of the hepatic phenotype, tested the association of these genetic variants with fatty liver disease (FLD),

    更新日期:2020-05-27
  • Hepatocyte KLF6 expression affects FXR signalling and the clinical course of primary sclerosing cholangitis
    Liver Int. (IF 5.542) Pub Date : 2020-05-27
    Svenja Sydor; Paul Manka; Lea van Buren; Sarah Theurer; Suzan Schwertheim; Jan Best; Janette Heegsma; Ali Saeed; Diana Vetter; Martin Schlattjan; Anna Dittrich; Maria Isabel Fiel; Hideo A. Baba; Alexander Dechêne; Francisco Javier Cubero; Guido Gerken; Ali Canbay; Han Moshage; Scott L. Friedman; Klaas Nico Faber; Lars P. Bechmann

    Primary sclerosing cholangitis (PSC) is characterized by chronic cholestasis and inflammation, which promotes cirrhosis and an increased risk of cholangiocellular carcinoma (CCA). The transcription factor Krueppel‐like‐factor‐6 (KLF6) is a mediator of liver regeneration, steatosis, and hepatocellular carcinoma (HCC), but no data is yet available on its potential role in cholestasis. Here, we aimed

    更新日期:2020-05-27
  • Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies
    Liver Int. (IF 5.542) Pub Date : 2020-05-27
    Elodie Beaumont; Benoit Joël Clément; Vanessa Guérin; Lucie Chopin; Emmanuelle Roch; Elsa Gomez‐Escobar; Philippe Roingeard

    The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine bearing genotype 1a HCV envelopes

    更新日期:2020-05-27
  • Reduced Iron Export Associated with Hepcidin Resistance Can Explain the Iron Overload Spectrum in Ferroportin Disease
    Liver Int. (IF 5.542) Pub Date : 2020-05-25
    André Viveiros; Marlene Panzer; Nadja Baumgartner; Benedikt Schaefer; Armin Finkenstedt; Benjamin Henninger; Igor Theurl; Karin Nachbaur; Günter Weiss; Roland Haubner; Clemens Decristoforo; Herbert Tilg; Heinz Zoller

    Ferroportin disease (FD) and hemochromatosis type 4 (HH4) are associated with variants in the ferroportin encoding gene SLC40A1 . Both phenotypes are characterized by iron overload despite being caused by distinct variants that either mediate reduced cellular iron export in FD or resistance against hepcidin‐induced inactivation of ferroportin in HH4. The aim of this study was to assess if reduced iron

    更新日期:2020-05-25
  • Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events.
    Liver Int. (IF 5.542) Pub Date : 2020-05-25
    Changhoon Yoo,Seonggyu Byeon,Yeonghak Bang,Jaekyung Cheon,Jin W Kim,Jee H Kim,Hong J Chon,Beodeul Kang,Myoung J Kang,Ilhwan Kim,Jun-Eul Hwang,Jung H Kang,Myung A Lee,Jung Y Hong,Ho Y Lim,Baek-Yeol Ryoo

    BACKGROUND & AIMS Regorafenib demonstrated a clinical benefit for patients with unresectable hepatocellular carcinoma (uHCC) in the phase III RESORCE trial. Considering the heterogeneity of uHCC and discrepancies in its characteristics between prospective trials and daily practice, real-life evidence is necessary. METHODS This multicentre, retrospective analysis was performed by the Korean Cancer Study

    更新日期:2020-05-25
  • Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts
    Liver Int. (IF 5.542) Pub Date : 2020-05-25
    Alessandra Mangia; Scott Milligan; Mandana Khalili; Stefano Fagiuoli; Stephen D Shafran; Fabrice Carrat; Denis Ouzan; George Papatheodoridis; Alnoor Ramji; Sergio M Borgia; Heiner Wedemeyer; Ruggero Losappio; Francisco Pérez‐Hernandez; Nicole Wick; Robert S Brown; Pietro Lampertico; Karen Doucette; Ioanna Ntalla; Heribert Ramroth; Michael Mertens; Kim Vanstraelen; Juan Turnes

    Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real‐world analysis to date, the effectiveness of pangenotypic, panfibrotic, single‐tablet, sofosbuvir/velpatasvir (SOF/VEL) once‐daily for 12 weeks was assessed in 12 clinical real‐world cohorts from various geographical areas, settings and

    更新日期:2020-05-25
  • Predicting microvascular invasion in HCC with ctDNA: What are the pitfalls?
    Liver Int. (IF 5.542) Pub Date : 2020-05-25
    Teh‐Ia Huo; Shu‐Yein Ho; Po‐Hong Liu

    We read with interest the paper “Preoperative evaluation of microvascular invasion with circulating tumor DNA in operable hepatocellular carcinoma” published in an upcoming issue of Liver International.1 It is an elegant study that looked at the association between microvascular invasion (MVI) and circular tumor DNA (ctDNA) for patients with surgical hepatocellular carcinoma (HCC) and their outcome

    更新日期:2020-05-25